On October 15, Johnson & Johnson announced its Q3 financial report for the quarter.Total Revenue$22.5 billion, year-on-yearIncrease by 5.2%.ItsIn China, pharmaceutical business revenue year-over-yearIncreased by 4.9% to USD 14.6 billion, mainly driven by Darzalex (Daratumumab）、Erleada (Apalutamide)And the strong growth of products like Caryvkti (Cilta-cel).
Anti-CD38 Monoclonal Antibody DArzalex has become Johnson & Johnson's top-selling drug in Q3 (+20.7%).，USD 3.016 billion), andStelara (Ustekinumab) has been impacted by the entry of biosimilars, affecting its sales.（26.$7.6 billion）Decreased by 6.6% year-on-year.Johnson & Johnson's Collaboration with LegendBCMA CAR-T Cell TherapyCaryvkti was the product with the strongest growth in Q3 (+87.7).%, 286 million USD).Caryvkti's total sales in the first three quarters of 2024 have reached$6.29 billion, an increase of 84.3% year-over-year.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
